Search results for "Continuation"

showing 10 items of 276 documents

Duality of moduli in regular toroidal metric spaces

2020

We generalize a result of Freedman and He [4, Theorem 2.5], concerning the duality of moduli and capacities in solid tori, to sufficiently regular metric spaces. This is a continuation of the work of the author and Rajala [12] on the corresponding duality in condensers. peerReviewed

30L10 30C65 28A75 51F99Pure mathematicsmetric spacesToroidDuality (optimization)torusMetric Geometry (math.MG)TorusArticlesmetriset avaruudetModulifunktioteoriaMetric spaceContinuationMathematics - Metric GeometrymodulusFOS: MathematicsdualitymittateoriageometriaMathematics::Symplectic GeometryMathematicsAnnales Fennici Mathematici
researchProduct

Redefining outcomes in immune TTP: an international working group consensus report

2021

Abstract Immune-mediated thrombotic thrombocytopenic purpura (iTTP) is a potentially fatal thrombotic microangiopathy caused by autoantibody-mediated severe deficiency of ADAMTS13. Standardized definitions of response, exacerbation, remission, and relapse were initially proposed in 2003 and modified by the International Working Group for TTP in 2017. These definitions, which have been widely used in clinical practice and research, are based primarily on the platelet count and are benchmarked against the timing of discontinuation of therapeutic plasma exchange (TPE). They do not incorporate ADAMTS13 activity or the temporizing effects on the platelet count of caplacizumab, a novel anti–von W…

Adult0301 basic medicinemedicine.medical_specialtyConsensusThrombotic microangiopathyExacerbation[SDV]Life Sciences [q-bio]ImmunologyThrombotic thrombocytopenic purpuraMEDLINEADAMTS13 Protein030204 cardiovascular system & hematologyBiochemistry03 medical and health sciences0302 clinical medicineFibrinolytic AgentsRecurrencehemic and lymphatic diseasesvon Willebrand FactorHumansMedicineClinical significanceIntensive care medicinePlasma ExchangePurpura Thrombotic ThrombocytopenicPlatelet Countbusiness.industryDisease ManagementCell BiologyHematologySingle-Domain Antibodiesmedicine.diseaseADAMTS133. Good healthDiscontinuationTreatment Outcome030104 developmental biologyFemaleCaplacizumabbusinessBlood
researchProduct

Acute, subchronic and discontinuation effects of zopiclone on sleep EEG and nocturnal melatonin secretion

1996

Zopiclone is a new short half-life cyclopyrrolone hypnotic agent acting at the GABA-benzodiazepine receptor complex. In order to characterize its pharmacological profile, the effects of 7.5 mg zopiclone on nocturnal melatonin secretion were investigated under polysomnographic control in 11 healthy subjects following acute and subchronic administration as well as after abrupt discontinuation of the drug. No effect of zopiclone on the melatonin plasma levels could be observed. Regarding both total melatonin production and the temporal pattern of melatonin secretion during the night, there was no difference between placebo baseline condition, acute and subchronic administration, and discontinu…

AdultDrugReceptor complexmedicine.medical_specialtyTime Factorsmedicine.drug_classmedia_common.quotation_subjectPharmacologyPlaceboPiperazinesHypnoticMelatoninInternal medicinemedicineHumansHypnotics and SedativesPharmacology (medical)ChildBiological PsychiatryMelatoninmedia_commonPharmacologyZopicloneElectroencephalographyDiscontinuationPsychiatry and Mental healthEndocrinologyNeurologyPharmacodynamicsNeurology (clinical)SleepPsychologyAzabicyclo Compoundsmedicine.drugEuropean Neuropsychopharmacology
researchProduct

Dropout from Court-Mandated Intervention Programs for Intimate Partner Violence Offenders: The Relevance of Alcohol Misuse and Cognitive Impairments

2019

There is considerable interest in offering insight into the mechanisms that might explain why certain perpetrators of intimate partner violence against women (IPVAW) drop out of interventions. Although several socio-demographic variables and attitudes towards IPVAW have been proposed as risk factors for IPVAW perpetrators&rsquo

AdultMale050103 clinical psychologymedicine.medical_specialtyHealth Toxicology and Mutagenesisintimate partner violencePsychological interventionlcsh:MedicinedropoutArticle03 medical and health sciences0302 clinical medicineBehavior TherapyRisk FactorsIntervention (counseling)medicineHumansCognitive Dysfunction0501 psychology and cognitive sciencesPsychiatryempathyDropout (neural networks)Consumption (economics)recidivismRecidivismalcohollcsh:R05 social sciencesPublic Health Environmental and Occupational HealthCognitionDiscontinuationAttitudeParellaDomestic violenceFemaleAlcoholPsychologyAlcohol-Related Disorders030217 neurology & neurosurgeryInternational Journal of Environmental Research and Public Health
researchProduct

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

2014

Abstract Differentiation syndrome (DS), formerly known as retinoic acid syndrome, is a relatively common and potentially severe complication seen in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and/or arsenic trioxide. The full-blown syndrome consists of unexplained fever, weight gain, dyspnea with pulmonary infiltrates, pleuropericardial effusion, hypotension, and renal failure. Most measures currently used for management of DS have very little evidence-based support, and therefore, many remain controversial. Despite the lack of evidence supporting DS prophylaxis, several groups have adopted a preventive strategy with corticosteroids, especially for patie…

AdultMaleAcute promyelocytic leukemiamedicine.medical_specialtyDrug-Related Side Effects and Adverse ReactionsPremedicationImmunologyTretinoinBiochemistryArsenicalslaw.inventionchemistry.chemical_compoundArsenic TrioxideLeukemia Promyelocytic AcutelawTretinoinInternal medicinemedicineHumansArsenic trioxideIntensive care medicineDexamethasonebusiness.industryOxidesSyndromeCell BiologyHematologymedicine.diseaseIntensive care unitDiscontinuationRetinoic acid syndromeLeukemiachemistryFemalebusinessmedicine.drugBlood
researchProduct

Benefits and risks of danazol in hereditary angioedema: a long-term survey of 118 patients

2008

Background Hereditary angioedema (HAE) due to C1 inhibitor deficiency is clinically characterized by relapsing skin swellings, abdominal pain attacks, and life-threatening upper airway obstruction. Treatment with androgens prevents attacks for those with this condition. Objective To examine the benefits and risks of long-term treatment with danazol. Methods Data were generated retrospectively from 118 German and Danish patients who had HAE due to C1 inhibitor deficiency and were treated with danazol from 2 months to 30 years. The frequency and severity of acute attacks were registered before and during danazol treatment, and adverse effects to the treatment were noted. Data were collected b…

AdultMalePulmonary and Respiratory Medicinemedicine.medical_specialtyAbdominal painPediatricsImmunologyDose-Response Relationship ImmunologicRisk AssessmentSeverity of Illness IndexEcallantideSeverity of illnessmedicineHumansImmunology and AllergyAdverse effectDepression (differential diagnoses)Retrospective StudiesDanazolbusiness.industryDanazolAngioedemas HereditaryEstrogen AntagonistsMiddle Agedmedicine.diseaseSurgeryDiscontinuationHereditary angioedemaFemalemedicine.symptombusinessFollow-Up Studiesmedicine.drugAnnals of Allergy, Asthma & Immunology
researchProduct

Time course of adverse events most commonly associated with topiramate for migraine prevention

2007

The efficacy, safety and tolerability of topiramate has been demonstrated in three large multicenter, randomized, double-blind, placebo-controlled trials. To characterize the time course of adverse events (AEs) that led to treatment discontinuation in/=2% of patients who received topiramate 100 mg/day during three pivotal, multicenter, randomized, double-blind, placebo-controlled, and 26-week trials. The pooled population comprised all randomized patients who reported safety data during the double-blind phase (topiramate 100 mg/day, n = 386; placebo n = 372), which consisted of a 4-week titration period and a 22-week maintenance period. Incidence, time to onset, and cumulative mean rate of …

AdultMaleTopiramateTime FactorsNauseaMigraine DisordersPopulationFructosePlaceboTimelaw.inventionPlacebosDouble-Blind MethodRandomized controlled trialTopiramatelawmedicineHumansParesthesiaeducationFatigueeducation.field_of_studyDose-Response Relationship Drugbusiness.industryNauseaMiddle Agedmedicine.diseaseAnorexiaDiscontinuationWithholding TreatmentNeurologyTolerabilityMigraineAnesthesiaPatient ComplianceAnticonvulsantsFemaleNeurology (clinical)medicine.symptomCognition Disordersbusinessmedicine.drugEuropean Journal of Neurology
researchProduct

Agomelatine and Hepatotoxicity: Implications of Cumulated Data Derived from Spontaneous Reports of Adverse Drug Reactions

2013

Considering the antidepressant agomelatine (AGM) there is a discrepancy between the widespread knowledge of the potential of AGM to cause hepatotoxic adverse drug reactions (ADR) and the availability of corresponding published data. This impedes an adequate assessment of the hepatotoxicity profile of AGM. We conducted a query of the database of a German Medical Regulatory Body (BfArM) and analyzed spontaneous reports of hepatotoxic ADR. We identified n=58 cases of AGM-related hepatotoxic ADR. Most frequent ADR was asymptomatic increase of liver enzymes (79%); n=6 patients (10%) with AGM-related toxic hepatitis were reported. Characteristics of patients: female sex (69%), age > 50 years (mea…

AdultMaleToxic hepatitismedicine.medical_specialtyDatabases FactualPharmacologyAsymptomaticLiver diseaseRisk FactorsGermanyInternal medicineAcetamidesPharmacovigilancemedicineHumansAgomelatinePharmacology (medical)ContraindicationAgedAged 80 and overPolypharmacybusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAntidepressive AgentsDiscontinuationPsychiatry and Mental healthFemaleChemical and Drug Induced Liver Injurymedicine.symptombusinessmedicine.drugPharmacopsychiatry
researchProduct

Prospective study on thyroid autoimmunity and dysfunction related to chronic hepatitis C and interferon therapy.

1997

This study was designed to assess patients with chronic hepatitis C (CHC) for the presence of thyroid autoimmunity and dysfunction, to evaluate the risk of thyroid disorders associated with interferon (IFN) therapy, and to survey the outcome of possible treatment-related thyroid injury. Out of 104 consecutive untreated patients (30 women and 74 men; mean age, 52.7 years), 8 (7.7%) were found seropositive for thyroid autoantibodies (ThyAb), whereas seropositivity in healthy controls was 1/98 (1.3%). The relative increase in risk of developing thyroid autoimmunity associated with CHC was 760% (95% Cl, 220–1300%). No patients had abnormalities of thyroid function tests, but on IFN treatment, 3…

AdultMaleendocrine systemmedicine.medical_specialtyendocrine system diseasesEndocrinology Diabetes and MetabolismThyroid GlandThyrotropinInterferon alpha-2Thyroid function testsGastroenterologyIodide PeroxidaseThyroiditisAutoimmune DiseasesAutoimmune thyroiditisEndocrinologyInternal medicinemedicineHumansProspective StudiesAutoantibodiesAutoimmune diseasemedicine.diagnostic_testbusiness.industryThyroidInterferon-alphaMiddle Agedmedicine.diseaseHepatitis CThyroid DiseasesAnti-thyroid autoantibodiesRecombinant ProteinsDiscontinuationThyroxinemedicine.anatomical_structureImmunologyTriiodothyronineFemaleThyroid functionbusiness
researchProduct

Adalimumab in steroid-dependent Crohn's disease patients: prognostic factors for clinical benefit.

2012

Background: Corticosteroids are effective in the treatment of Crohn's disease but some patients relapse during tapering or after discontinuation. We report data on efficacy and prognostic factors of response of adalimumab in steroid-dependent patients. Methods: In all, 110 steroid-dependent patients were treated with adalimumab (80/40 or 160/80 mg every other week followed by 40 mg every other week). Clinical remission was defined as steroid discontinuation without symptomatic recurrence and clinical response as the reduction or maintenance of the initial Crohn's Disease Activity Index (CDAI) value reducing steroid dosage but without its discontinuation at week 6 and at the end of follow-up…

AdultMalemedicine.medical_specialtyAdolescentAnti-Inflammatory AgentsAntibodies Monoclonal HumanizedInflammatory bowel diseaseYoung AdultCrohn DiseaseInternal medicinemedicineAdalimumabSecondary PreventionImmunology and AllergyHumansProspective StudiesYoung adultProspective cohort studyGlucocorticoidsAgedUnivariate analysisCrohn's diseasebusiness.industryRemission InductionGastroenterologyAdalimumabMiddle Agedmedicine.diseasePrognosisSurgeryDiscontinuationRegimenFemalebusinessmedicine.drugFollow-Up StudiesInflammatory bowel diseases
researchProduct